Burkina Faso, Cameroon and Uganda made their first-ever pledge to Gavi, the Vaccine Alliance joining world leaders to pledge US$ 8.8 billion for a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases.
The funding will help immunise 300 million more children in the world’s poorest countries against diseases like measles, polio and diphtheria by the end of 2025. It will also support health systems to withstand the impact of coronavirus and maintain the infrastructure necessary to roll out a future COVID-19 vaccine on a global scale.
Over the next five years, we will also see the largest investment in immunisation ever made by lower-income countries.
Gavi-supported countries will contribute US$ 3.6 billion towards the cost of buying vaccines – more than double the amount for the 2016-2020 period and more than 40% of the total estimated cost of supplying vaccines to these countries. They are also expected to invest around US$ 6 billion in immunisation service delivery costs over the same period. The dire economic effects of the COVID-19 pandemic may, however, disrupt these estimates.
Gavi’s market-shaping efforts to make life-saving vaccines more affordable have seen a 21% price reduction for fully immunising a child with pentavalent, pneumococcal and rotavirus vaccines – from $20.01 in 2015 to $15.90 in 2018.
“COVID-19 is a brutal reminder of why we must prioritise health,” said Roch Marc Christian Kaboré, President of Burkina Faso. “But if we fail to maintain the achievements we have made in vaccination, we risk the resurgence of deadly diseases like measles, yellow fever and polio. By working together to ensure the survival and prosperity of the people of Burkina Faso, of Africa and of the world, we will together write the most magnificent pages in our common history.”
The pledges were made at the Global Vaccine Summit 2020, hosted by UK Prime Minister Boris Johnson. Representatives from 52 countries, including 35 Heads of State, joined leaders from global health organisations, the private sector, vaccine manufacturers and civil society organisations to support the Vaccine Alliance’s work protecting almost half the world’s children against deadly, preventable infectious diseases.
Gavi, the World Health Organization (WHO) and UNICEF have warned that 80 million children under the age of one are at risk of disease due to disruptions to vital immunisation programmes because of COVID-19.
The UK remains the Vaccine Alliance’s largest donor, pledging the equivalent of £330 million per year over the next five years.
As well as supporting the routine vaccination of hundreds of millions of children in lower-income countries from infectious diseases, the new support will also be used to help lower-income countries meet the challenge of the coronavirus pandemic by strengthening health systems and vaccine distribution.
“Britain has been honoured to host this summit today,” said Boris Johnson, UK Prime Minister. “You can count on our full contribution as together we rise to fulfil the greatest shared endeavour of our lifetime – the triumph of humanity over disease, now and for the generations that follow. As we make the choice today to unite and forge a path of global co-operation, let us also renew our collective resolve to find the vaccine that can defeat coronavirus.”
Included in the total figure is US$ 0.9 billion in long-term pledges made to the innovative International Finance Facility for Immunisation (IFFIm), which will be used when needed to raise immediate funds on the capital markets.
“As the world battles against coronavirus, today’s UK-hosted Global Vaccine Summit has been a superb example of what we can achieve when we all take action together,” said Anne-Marie Trevelyan, UK International Development Secretary. “We know vaccines work, and I’m incredibly proud that we’ve exceeded Gavi’s pledging target to help protect 300 million more children from deadly illnesses through routine immunisation. This will help stop the spread of infection around the world, now, and in the future.”
The world’s biggest vaccine manufacturers also committed to continuing supplying the billions of doses needed to continue increasing vaccine coverage across Africa and Asia. The Vaccine Alliance is one of the world’s largest and most successful public-private partnerships, and the wider private sector continued to show support for its mission with the announcement of more than US$ 70 million of new pledges and partnerships, bringing new technology, networks and expertise to help solve some of the global health’s most intractable problems.
“On behalf of the countless vaccinators, supply chain workers, programme managers and the many, many others that work tirelessly every day to ensure children in vulnerable countries continue to receive lifesaving vaccines – thank you,” said Dr Ngozi Okonjo-Iweala, Gavi Board Chair. “We have made incredible progress over the past two decades improving vaccine coverage and reducing child mortality across Africa and Asia. This funding will give countries new hope that, despite the devastating impact of COVID-19, this progress can be sustained and built on. The Alliance will now get to work making this happen.”
The Global Vaccine Summit also saw the launch of the Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC), a new innovative financing instrument to provide access to COVID-19 vaccines for low- and middle-income countries. This is the first building block towards a global mechanism to ensure equitable access to future COVID-19 vaccines. US$ 567 million was raised today in initial seed money for the AMC from 12 donors.
“As we celebrate a historic day we must also turn towards our next challenge: ensuring universal access to COVID-19 vaccines,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “One thing that has been made all too clear over the past few months is that this disease does not respect borders, which is why this global problem requires a global solution. After today’s success, we now need support to help ensure the most vulnerable people in low- and middle-income countries – as well as those in high- and upper-middle-income countries – have access to COVID-19 vaccines.”